1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
+Added: On August 11, 2025 , Evert Schimmelpennink , Chief Executive Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: This 10b5-1 trading plan provides for the sale of 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr.
+Added: Schimmelpennink.
+Added: This 10b5-1 trading plan will become effective on January 19, 2026 and will terminate on June 30, 2026 , subject to earlier termination as provided in the plan.
+Added: On August 12, 2025 , Shawn Olsson , Chief Commercial Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: This 10b5-1 trading plan provides for the sale of 66,891 shares of the Company’s common stock related to the exercise of option awards granted to Mr.
+Added: This 10b5-1 trading plan will become effective on November 17, 2025 and will terminate on October 19, 2026 , subject to earlier termination as provided in the plan.
+Added: During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
3.1 Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024).
1 unchanged sentence
4.1 Form of Warrant to Purchase Shares of Series A Preferred Stock (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-4 filed with the SEC on December 6, 2023).
−Removed: 10.1 Sales Agreement, dated April 4, 2025, between LENZ Therapeutics, Inc.
−Removed: and TD Securities (USA) LLC (incorporated by reference to Exhibit 1.1 to the Company's Form 8-K filed with the SEC on April 4, 2025).
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
16 unchanged sentences
LENZ THERAPEUTICS, INC.
−Removed: July 30, 2025
+Added: November 5, 2025
/s/ Evert Schimmelpennink
2 unchanged sentences
(Principal Executive Officer)
−Removed: July 30, 2025
+Added: November 5, 2025
/s/ Daniel Chevallard
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.